ReviewExpert opinion on biological therapy2010
Teplizumab therapy for type 1 diabetes.
Review in Expert opinion on biological therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.Cellular immunology · 2017Trial
- Combination of proton-pump inhibitor and anti-CD3 F(ab')Immunotherapy advances · 2026Article
- Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review.World journal of diabetes · 2024Article
- Untangling the genetics of beta cell dysfunction and death in type 1 diabetes.Molecular metabolism · 2024Review
- Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis.World journal of diabetes · 2024Article
- Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.TouchREVIEWS in endocrinology · 2023Review
- Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.Diabetes care · 2023Article
- Teplizumab: type 1 diabetes mellitus preventable?European journal of clinical pharmacology · 2023Review
- Engineering the lymph node environment promotes antigen-specific efficacy in type 1 diabetes and islet transplantation.Nature communications · 2023Article
- Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.Acta biomaterialia · 2021Review
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.International journal of molecular sciences · 2021Review
- Protein-engineered molecules carrying GAD65 epitopes and targeting CD35 selectively down-modulate disease-associated human B lymphocytes.Clinical and experimental immunology · 2019Article
- Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells.Journal of the American Heart Association · 2018Article
- Combination Immunotherapy for Type 1 Diabetes.Current diabetes reports · 2017Review
- Red carpeting the newer antidiabetics.Journal of pharmacology & pharmacotherapeutics · 2012Article
- Prevention of Type 1 Diabetes: Current Perspective.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldType 1 diabetes mellitus (T1D) is a T-cell mediated autoimmune disease with selective destruction of beta cells. Immunological interventions are directed at arresting the loss of beta-cell function with the promise that this will make it easier for patients to control their glucose levels. AREAS COVERED IN THIS REVIEW: This review provides a summary of the preclinical and clinical research published between 1992 and 2009 using teplizumab and other anti-CD3 antibodies to arrest the loss of beta-cell function in new onset T1D. Data from animal and human studies on the probable mechanism of action of teplizumab are also reviewed. WHAT THE READER WILL GAIN: A broad perspective on the use of teplizumab in inducing disease specific tolerance. TAKE HOME MESSAGE: In Phase I/II randomized control trials, in patients with new onset T1D, teplizumab slowed the rate of loss of beta-cell function over 2 years of follow-up. Treated patients had better glycemic control and lower insulin requirements. Adverse events so far are mild and of limited duration. Phase III clinical trials are underway to confirm these results and to determine if two courses of drug have greater efficacy in arresting loss of beta-cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.